skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

London – 5 April, 2019 – Informa Pharma Intelligence is pleased to announce that The Global Generics & Biosimilars Awards 2019 will be held on Tuesday, November 5, 2019. The ceremony for this year’s awards, which recognize and promote best practices in the generics and biosimilars industries, will take place in Frankfurt, Germany.
“We are looking forward to welcoming the best and brightest of the generics and biosimilars industries to the Global Generics & Biosimilars Awards in Frankfurt this November,” said Generics Bulletin Executive Editor David Wallace. “This is the one night of the year where we gather to celebrate the many achievements made by these industries, and I’m sure competition across all categories will be as strong as ever.”

Since 2014, the annual Global Generics & Biosimilars awards has gathered leaders from across the generics and biosimilars industries to celebrate the exceptional contributions of those working worldwide to make medicines more affordable.

The awards span 14 different categories, with a focus on excellence in business development initiatives such as innovative product development, clever licensing deals, or smart legal maneuvers. 2019 marks the introduction of two new categories: Value-Added Medicine Initiative of the Year and Legal Strategy of the Year. Each of the awards honors those who are making and encouraging improvements to every aspect of the way business in the biosimilars and generics industries is conducted.
For a full list of awards categories and information about how to enter a nomination, visit https://pharmaintelligence.informa.com/events/awards/global-generics-and-biosimilars-awards-2019.

“The Global Generics & Biosimilars Awards has become bigger and better every year,” Wallace highlighted, “and we can’t wait for the industry to get together again in November for what promises to be an exciting evening, a great opportunity to meet industry peers, and the best way to promote and celebrate your company’s successes.”


About Informa Pharma Intelligence

Trusted by over 3,000 of the world’s leading pharmaceutical companies, CROs, med and biotech organizations, and healthcare service providers, the Pharma Intelligence suite of intelligence solutions delivers vital, accurate, and timely intelligence about the drug development pipeline to pharmaceutical and biomedical decision makers around the world.
At Pharma Intelligence, global teams of subject area experts follow and analyze key diseases, clinical trials, drug approvals and R&D activities as part of the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

About Generics Bulletin

For more than 15 years, Generics Bulletin has been bringing subscribers comprehensive coverage of the global generics, biosimilars, and value-added medicines industries. Part of the Informa Pharma Intelligence suite of industry intelligence solutions, Generics Bulletin provides news and analysis to aide decision makers in understanding the implications of industry developments and trends. Coverage includes news and interviews with key opinion leaders.

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: